Head and Neck
HNSCC, nasopharyngeal, salivary, thyroid
DefinitionClick to collapse
Head and neck cancers encompass a diverse group of malignancies arising from the mucosal surfaces of the upper aerodigestive tract. The oral cavity (including mucosal lip) comprises the buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, and hard palate [OR-1]. The oropharynx includes the base of tongue, tonsils, soft palate, and posterior pharyngeal wall [ORPH-1]. The hypopharynx extends from the hyoid bone to the cricoid cartilage and is divided into pyriform sinus, posterior pharyngeal wall, and postcricoid area [HYPO-1]. The nasopharynx is the uppermost part of the pharynx, posterior to the nasal cavity, and is strongly associated with Epstein-Barr virus (EBV) infection [NASO-1]. The larynx is subdivided into supraglottis, glottis, and subglottis [GLOT-1, SUPRA-1]. Paranasal sinus tumors arise from the ethmoid and maxillary sinuses [ETHM-1, MAXI-1]. Salivary gland tumors originate from major (parotid, submandibular, sublingual) or minor salivary glands distributed throughout the aerodigestive tract [SALI-1]. Mucosal melanoma of the head and neck occurs in the sinonasal tract, oral cavity, pharynx, and larynx [MM-1]. Occult primary cancer is defined as metastatic carcinoma in a cervical lymph node without an identifiable primary site after thorough investigation [OCC-1]. Squamous cell carcinoma (SCC) accounts for >90% of these tumors [Discussion, MS-1]. Embryologically, these structures derive from the pharyngeal arches, pouches, and foregut endoderm, with distinct anatomical boundaries defined by the AJCC staging system [ST-1 to ST-19].
EpidemiologyClick to collapse
In 2026, an estimated 72,770 new cases of oral cavity, pharyngeal, and laryngeal cancers and 17,110 deaths are projected in the United States, accounting for approximately 3.4% of new cancer cases [Discussion MS-2; Siegel et al. 2026, reference 1]. The incidence of HPV-positive oropharyngeal cancer is increasing, particularly in men, while HPV-negative (tobacco/alcohol-related) cancer is declining [Discussion MS-3; Chaturvedi et al. J Clin Oncol 2011;29:4294-4301, reference 14]. The attributable fraction of HPV in oropharyngeal cancer is approximately 90% in the United States and parts of Europe [Discussion MS-3]. Patients with HPV-positive cancer tend to be younger (median age at diagnosis 60-64 years) and have better prognosis, while HPV-negative patients are older (median age 66 years) and have higher risk of second primaries [Discussion MS-3]. Oral cavity cancer has a higher incidence in males, with strong racial disparities: Black men have higher rates of oral cavity and pharyngeal cancers compared to White men. Laryngeal cancer incidence is 4-5 times higher in males than females, with highest rates in Black males [ST-8]. Nasopharyngeal carcinoma is rare in the United States but endemic in Southeast Asia, southern China, North Africa, and the Arctic, with incidence rates 20-50 per 100,000 in high-risk regions; rates in the US are <1 per 100,000 [Discussion MS-41]. The male-to-female ratio is 2-3:1 for nasopharyngeal carcinoma. For paranasal sinus cancers, the age-adjusted incidence is very low (<1 per 100,000); ethmoid sinus tumors are rarer than maxillary sinus tumors. Mucosal melanoma accounts for <1% of all melanoma cases but has a poor prognosis; the incidence of sinonasal mucosal melanoma is increasing [Discussion MS-65]. Salivary gland tumors have an annual incidence of about 3 per 100,000; 20% of parotid tumors are malignant, rising to 50% for submandibular and 80% for minor salivary gland tumors [Discussion MS-62]. Occult primary head and neck cancer accounts for approximately 5% of patients presenting to referral centers [Discussion MS-60].
SubtypesClick to collapse
Molecular PathogenesisClick to collapse
Head and neck squamous cell carcinoma (HNSCC) develops through two major molecular pathways: HPV-associated and HPV-unrelated. HPV-positive oropharyngeal cancers are driven by expression of the E6 and E7 oncogenes, which inactivate tumor suppressor proteins p53 and pRb, respectively, leading to genomic instability. Upregulation of p16 protein, a surrogate marker of HPV DNA, results from pRb inactivation. Genetic profiling shows HPV-positive tumors are molecularly distinct from HPV-negative HNSCC, with fewer TP53 mutations but frequent alterations in PIK3CA (activating mutations) and loss of TRAF3 [Discussion MS-3]. HPV-negative HNSCC is characterized by mutations in TP53 (85-90% of tumors), CDKN2A (p16) inactivation, and amplification of CCND1 and EGFR. EGFR overexpression is common and associated with poor prognosis [Discussion MS-21]. Promoter mutations in TERT are frequent. Whole-exome sequencing has identified recurrent alterations in NOTCH1, FAT1, and CASP8. For salivary gland tumors, translocations are hallmark events: mucoepidermoid carcinoma has CRTC1-MAML2 fusion; adenoid cystic carcinoma shows MYB-NFIB fusion; secretory carcinoma (mammary analogue) has ETV6-NTRK3 fusion. Salivary duct carcinoma frequently shows HER2 amplification and androgen receptor expression [SALI-B]. Sinonasal undifferentiated carcinoma (SNUC) may harbor IDH2 R172X mutations. NUT midline carcinoma is defined by NUTM1 rearrangements. Mucosal melanoma shows distinct genomic features: frequent mutations in NRAS (15-19%), KIT (7-26%), and NF1 (18%), with lower BRAF mutation rates (5-8%) compared to cutaneous melanoma [Discussion MS-65]. Recurrent amplifications of CDK4, MDM2, and TERT are common. In nasopharyngeal carcinoma, EBV infection is a key etiologic factor, with latent membrane protein 1 (LMP1) driving NF-κB signaling and genomic instability.
Risk FactorsClick to collapse
Tobacco use (cigarettes, cigars, pipes, smokeless tobacco)
Strongly associated with oral cavity, oropharynx (HPV-negative), hypopharynx, larynx, and nasopharynx cancers. Risk increases with duration and intensity (pack-years). Smoking decreases efficacy of radiotherapy and adversely affects survival [Discussion MS-5, MS-21].
Alcohol consumption
Synergistic with tobacco; particularly for oral cavity, oropharynx, hypopharynx, and larynx cancers. Heavy drinking (≥3 drinks/day) significantly increases risk [Discussion MS-5].
Human papillomavirus (HPV) infection, especially HPV16
Primary cause of oropharyngeal squamous cell carcinoma (tonsil and base of tongue). HPV16 accounts for ~90% of HPV-positive cases. Oral HPV infection increases risk of oropharyngeal cancer [Discussion MS-3].
Epstein-Barr virus (EBV) infection
Key etiologic factor for nasopharyngeal carcinoma, particularly in endemic regions. EBV DNA detectable in tumor tissue and plasma; high viral load associated with worse prognosis [Discussion MS-41].
Occupational exposures (wood dust, leather, nickel, formaldehyde)
Specifically for sinonasal cancers. Wood dust exposure is strongly linked to adenocarcinoma of the ethmoid sinus. Nickel refining, leather dust, and formaldehyde are also associated [Discussion MS-52].
Genetic predisposition
Family history of head and neck cancer increases risk. Patients with Fanconi anemia, dyskeratosis congenita, and Li-Fraumeni syndrome have elevated risk. Genome-wide association studies have identified risk loci at 4q21, 4q25, 12q24, and other regions [OR-1].
Male sex
Incidence rates 2-4 times higher in men across most subsites. For oropharyngeal cancer, the male-to-female ratio is 4-5:1 for HPV-positive cases [Discussion MS-3].
Immunosuppression (HIV/AIDS, organ transplantation)
Increased risk of HPV-related head and neck cancers. HIV-positive individuals have higher rates of oral and oropharyngeal cancers [Discussion MS-4].
Betel quid and areca nut chewing
Common in South and Southeast Asia; associated with oral cavity and oropharyngeal cancers. Synergistic with tobacco and alcohol [Discussion MS-5].
Poor oral hygiene and chronic irritation
Chronic dental trauma, poor dental status, and chronic oral infections may contribute to oral cavity cancer risk [Discussion MS-31].
Clinical FeaturesClick to collapse
Typical Presentation
Head and neck cancers encompass diverse subsites with distinct presentations. Oral cavity cancers (buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, hard palate) typically present as a non-healing ulcer or mass, with pain, dysphagia, or odynophagia [OR-1]. Oropharyngeal cancers (base of tongue, tonsil, soft palate, posterior pharyngeal wall) often present with a neck mass, especially in HPV-positive disease, along with sore throat, dysphagia, or otalgia [ORPH-1]. HPV-positive oropharyngeal cancer is increasing in incidence, especially in men, and patients tend to be younger with less tobacco exposure [Discussion MS-3]. HPV-negative oropharyngeal cancer is linked to tobacco and alcohol, presenting with larger primaries and worse prognosis. Laryngeal cancers: glottic tumors cause early hoarseness, while supraglottic tumors present with dysphagia, otalgia, or neck mass; subglottic tumors are rare and present with stridor or dyspnea [GLOT-1, SUPRA-1]. Hypopharyngeal cancers (pyriform sinus, postcricoid, posterior pharyngeal wall) often present late with dysphagia, odynophagia, referred otalgia, and neck mass; prognosis is poor [HYPO-1]. Nasopharyngeal carcinoma (NPC) is endemic in Southeast Asia and associated with EBV; classic presentation includes cervical lymphadenopathy, epistaxis, nasal obstruction, conductive hearing loss, and cranial neuropathies [NASO-1]. Sinonasal tumors (ethmoid and maxillary sinus) present with unilateral nasal obstruction, epistaxis, facial pain, or proptosis; histologies include squamous cell carcinoma, adenocarcinoma, esthesioneuroblastoma, and undifferentiated carcinoma [ETHM-1, MAXI-1]. Salivary gland tumors (parotid, submandibular, minor) typically present as a painless, slow-growing mass; malignancy is suspected with facial nerve palsy, rapid growth, or fixation [SALI-1]. Occult primary presents as a cervical lymph node metastasis without an identifiable primary after thorough workup [OCC-1]. Mucosal melanoma of the head and neck presents as a pigmented or non-pigmented lesion in the nasal cavity, sinuses, or oral cavity, often with epistaxis or mass [MM-1].
Symptoms
Neck mass
Painless or painful cervical lymphadenopathy, often firm or fixed, may be cystic in HPV-positive oropharyngeal cancer.
Hoarseness
Change in voice quality lasting >3 weeks; common in glottic laryngeal cancer.
Dysphagia/Odynophagia
Pain or difficulty swallowing, often with referred otalgia.
Oral ulcer or mass
Non-healing ulcer, erythroplakia, or leukoplakia in the oral cavity.
Epistaxis and nasal obstruction
Unilateral epistaxis, nasal congestion, or discharge.
Otalgia
Referred ear pain, often unilateral, without otoscopic findings.
Cranial neuropathy
Facial numbness, diplopia, or other cranial nerve deficits.
Signs
Visible or palpable primary lesion
Ulcerated, exophytic, or infiltrative mass in oral cavity, oropharynx, or larynx on examination.
Cervical lymphadenopathy
Enlarged, firm, or matted lymph nodes in the neck; may be cystic in HPV-positive disease.
Vocal cord immobility
Impaired or fixed vocal cord on laryngoscopy, indicating paraglottic space invasion.
Trismus
Limited mouth opening due to pterygoid muscle invasion.
Facial nerve palsy
Weakness of facial muscles, usually in parotid malignancies.
Proptosis or periorbital swelling
Forward displacement of the eye or eyelid edema due to orbital invasion.
Red FlagsClick to collapse
Persistent hoarseness >3 weeks, especially in smokers or drinkers [GLOT-1].
Unilateral neck mass >2 cm that persists >2 weeks, particularly if firm, fixed, or matted [ORPH-1, OCC-1].
Non-healing oral ulcer >2 weeks, especially with exophytic growth or bleeding [OR-1].
Progressive dysphagia or odynophagia with unintentional weight loss [HYPO-1].
Unilateral otalgia without ear pathology, particularly with concomitant throat symptoms [ORPH-1].
Epistaxis or nasal obstruction that is unilateral, persistent, or associated with cranial neuropathy or facial numbness [NASO-1, ETHM-1].
Facial nerve palsy (VII) in the setting of a parotid mass [SALI-1].
Trismus, proptosis, or periorbital edema suggesting advanced disease [ADV-1].
Cranial nerve deficits (II–VI, IX–XII) without clear alternate cause [NASO-1].
New onset serous otitis media in an adult (>40 years), especially unilateral, should prompt nasopharyngeal evaluation [NASO-1].
InvestigationsClick to collapse
Diagnostic
History and physical examination
Complete head and neck exam including mirror and fiberoptic laryngoscopy/nasopharyngoscopy to visualize primary site and assess nodal basins.
Biopsy of primary site or fine-needle aspiration (FNA) of neck node
Histopathologic confirmation of malignancy; FNA is preferred for neck masses. Image-guided (US or CT) needle biopsy improves yield for cystic nodes.
CT with contrast of primary and neck
Evaluate tumor extent, bone erosion, cartilage invasion, nodal disease. Thin cuts (<1.25 mm) for laryngeal assessment.
MRI with and without contrast of primary and neck
Preferred for skull base, perineural spread, intracranial extension, bone marrow invasion, and differentiating tumor from obstructed sinuses.
FDG-PET/CT
Higher sensitivity for nodal and distant metastases; preferred for staging locoregionally advanced disease (T3–4 or N+) and for unknown primary.
Examination under anesthesia (EUA) with endoscopy
Direct visualization, palpation, and biopsy of suspicious areas; essential for occult primary workup.
Chest CT (with or without contrast)
Assess for pulmonary metastases or mediastinal adenopathy; also screens for second primary lung cancer.
Panoramic dental x-ray (Panorex) or dental CT
Pre-treatment dental evaluation for oral cavity cancers requiring mandibulectomy or when postoperative RT is anticipated.
Staging
CT with contrast of neck and primary
Defines tumor size, extension, and nodal characteristics including extranodal extension.
MRI with contrast of neck and primary
Superior soft tissue contrast for perineural and bone marrow assessment.
FDG-PET/CT
Whole-body staging with high sensitivity for nodal and distant disease.
Chest CT with contrast or non-contrast low-dose CT
Evaluate pulmonary metastases and mediastinal adenopathy.
Brain MRI with contrast
High sensitivity for brain and meningeal involvement.
EBV DNA testing (plasma)
Elevated pretreatment EBV DNA correlates with stage and survival; post-treatment levels guide surveillance.
Biomarkers
p16 immunohistochemistry (IHC)
Surrogate marker for HPV-mediated oropharyngeal cancer; required for oropharyngeal primaries.
HPV-specific testing (PCR or RNA ISH)
Confirmatory when p16 IHC is discordant or in clinical trials; recommended in low-prevalence regions or for non-oropharyngeal sites.
Epstein-Barr virus (EBV) testing (EBER ISH or PCR)
Detects EBV in tumor tissue; essential for nasopharyngeal carcinoma diagnosis and risk stratification.
PD-L1 IHC (CPS)
Guides use of pembrolizumab in recurrent/metastatic SCC; required for first-line immunotherapy decisions.
Multigene panel testing (MGPT) / NGS
Identifies actionable biomarkers including HER2, NTRK, FGFR, BRAF, RET, MSI, TMB, dMMR; guides targeted therapy in recurrent/metastatic disease.
Tumor mutational burden (TMB) and MSI/MMR testing
Identifies patients eligible for pembrolizumab (TMB-H ≥10 mut/Mb, MSI-H/dMMR).
Androgen receptor (AR) testing
For salivary duct carcinoma; guides hormone therapy.
HER2 testing (IHC/ISH)
For salivary gland tumors; guides trastuzumab-based therapy.
StagingClick to collapse
American Joint Committee on Cancer (AJCC) 8th and 9th editions, TNM classification. For most head and neck sites, AJCC 8th edition is used (oral cavity, oropharynx p16-negative, hypopharynx, larynx, nasal cavity/paranasal sinuses, major salivary glands, mucosal melanoma, occult primary). For nasopharynx, AJCC 9th edition (2021) is now adopted. For HPV-mediated oropharyngeal cancer, AJCC 8th edition with separate staging is used, but 9th edition updates are noted. [ST-1 through ST-19]
T Categories
| Stage | Description |
|---|---|
| TX | Primary tumor cannot be assessed. |
| Tis | Carcinoma in situ. |
| T1 – Oral Cavity | Tumor ≤2 cm with depth of invasion (DOI) ≤5 mm. |
| T2 – Oral Cavity | Tumor ≤2 cm with DOI >5 mm, or tumor >2 cm and ≤4 cm with DOI ≤10 mm. |
| T3 – Oral Cavity | Tumor >2 cm and ≤4 cm with DOI >10 mm, or tumor >4 cm with DOI ≤10 mm. |
| T4a – Oral Cavity | Moderately advanced local disease: tumor >4 cm with DOI >10 mm or invades adjacent structures (through cortical bone of mandible/maxilla, maxillary sinus, skin of face). Superficial erosion of bone/tooth socket alone by gingival primary is not T4. |
| T4b – Oral Cavity | Very advanced local disease: tumor invades masticator space, pterygoid plates, skull base, and/or encases internal carotid artery. |
| T1 – Oropharynx (p16-negative) | Tumor ≤2 cm in greatest dimension. |
| T2 – Oropharynx (p16-negative) | Tumor >2 cm but ≤4 cm. |
| T3 – Oropharynx (p16-negative) | Tumor >4 cm or extension to lingual surface of epiglottis. |
| T4a – Oropharynx (p16-negative) | Moderately advanced: tumor invades larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. |
| T4b – Oropharynx (p16-negative) | Very advanced: tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base, or encases carotid artery. |
| T1 – HPV-mediated Oropharynx | Tumor ≤2 cm in greatest dimension. |
| T2 – HPV-mediated Oropharynx | Tumor >2 cm but ≤4 cm. |
| T3 – HPV-mediated Oropharynx | Tumor >4 cm or extension to lingual surface of epiglottis. |
| T4 – HPV-mediated Oropharynx | Moderately advanced local disease: tumor invades larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, mandible, or beyond. T4b is not used for HPV-mediated disease; all T4 is considered T4. |
| T1 – Hypopharynx | Tumor limited to one subsite of hypopharynx and/or ≤2 cm. |
| T2 – Hypopharynx | Tumor invades more than one subsite or adjacent site, or >2 cm but ≤4 cm without fixation of hemilarynx. |
| T3 – Hypopharynx | Tumor >4 cm or with fixation of hemilarynx or extension to esophageal mucosa. |
| T4a – Hypopharynx | Moderately advanced: tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, esophageal muscle, or central compartment soft tissue. |
| T4b – Hypopharynx | Very advanced: tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures. |
| Tis – Larynx (Glottic/Supraglottic/Subglottic) | Carcinoma in situ. |
| T1 – Supraglottis | Tumor limited to one subsite of supraglottis with normal vocal cord mobility. |
| T2 – Supraglottis | Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside supraglottis (e.g., base of tongue, vallecula, medial wall of pyriform sinus) without fixation. |
| T3 – Supraglottis | Tumor limited to larynx with vocal cord fixation and/or invades postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. |
| T4a – Supraglottis | Moderately advanced: tumor invades through outer cortex of thyroid cartilage and/or invades tissues beyond larynx (trachea, soft tissues of neck, strap muscles, thyroid, esophagus). |
| T4b – Supraglottis | Very advanced: tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. |
| T1 – Glottis | Tumor limited to vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. T1a: one cord; T1b: both cords. |
| T2 – Glottis | Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. |
| T3 – Glottis | Tumor limited to larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of thyroid cartilage. |
| T4a – Glottis | Moderately advanced: tumor invades through outer cortex of thyroid cartilage and/or invades tissues beyond larynx (trachea, cricoid cartilage, soft tissues of neck, strap muscles, thyroid, esophagus). |
| T4b – Glottis | Very advanced: tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. |
| T1 – Subglottis | Tumor limited to subglottis. |
| T2 – Subglottis | Tumor extends to vocal cord(s) with normal or impaired mobility. |
| T3 – Subglottis | Tumor limited to larynx with vocal cord fixation and/or inner cortex of thyroid cartilage. |
| T4a – Subglottis | Moderately advanced: tumor invades cricoid or thyroid cartilage and/or invades tissues beyond larynx (trachea, soft tissues of neck, strap muscles, thyroid, esophagus). |
| T4b – Subglottis | Very advanced: tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. |
| T1 – Nasopharynx (AJCC 9th ed.) | Tumor confined to nasopharynx, or extension to oropharynx and/or nasal cavity without parapharyngeal involvement. |
| T2 – Nasopharynx (9th ed.) | Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). |
| T3 – Nasopharynx (9th ed.) | Tumor with unequivocal infiltration of bony structures at skull base, cervical vertebra, pterygoid structures, and/or paranasal sinuses. |
| T4 – Nasopharynx (9th ed.) | Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the anterolateral surface of the lateral pterygoid muscle. |
| T1 – Maxillary Sinus | Tumor limited to maxillary sinus mucosa with no erosion or destruction of bone. |
| T2 – Maxillary Sinus | Tumor causing bone erosion or destruction including extension into hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. |
| T3 – Maxillary Sinus | Tumor invades bone of posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses. |
| T4a – Maxillary Sinus | Moderately advanced: tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses. |
| T4b – Maxillary Sinus | Very advanced: tumor invades orbital apex, dura, brain, middle cranial fossa, cranial nerves other than V2, nasopharynx, or clivus. |
| T1 – Ethmoid Sinus/Nasal Cavity | Tumor restricted to any one subsite, with or without bony invasion. |
| T2 – Ethmoid Sinus/Nasal Cavity | Tumor invading two subsites within a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. |
| T3 – Ethmoid Sinus/Nasal Cavity | Tumor extends to invade medial wall or floor of orbit, maxillary sinus, palate, or cribriform plate. |
| T4a – Ethmoid Sinus/Nasal Cavity | Moderately advanced: tumor invades anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses. |
| T4b – Ethmoid Sinus/Nasal Cavity | Very advanced: tumor invades orbital apex, dura, brain, middle cranial fossa, cranial nerves other than V2, nasopharynx, or clivus. |
| T1 – Major Salivary Glands | Tumor ≤2 cm in greatest dimension without extraparenchymal extension. |
| T2 – Major Salivary Glands | Tumor >2 cm but ≤4 cm without extraparenchymal extension. |
| T3 – Major Salivary Glands | Tumor >4 cm and/or having extraparenchymal extension. |
| T4a – Major Salivary Glands | Moderately advanced: tumor invades skin, mandible, ear canal, and/or facial nerve. |
| T4b – Major Salivary Glands | Very advanced: tumor invades skull base and/or pterygoid plates and/or encases carotid artery. |
| T3 – Mucosal Melanoma of Head and Neck | Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension (e.g., polypoid nasal disease, pigmented or nonpigmented lesions of oral cavity, pharynx, larynx). |
| T4a – Mucosal Melanoma | Moderately advanced: tumor involving deep soft tissue, cartilage, bone, or overlying skin. |
| T4b – Mucosal Melanoma | Very advanced: tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures. |
| T0 – Occult Primary (Cervical Lymph Node) | No primary tumor identified after appropriate workup; used for staging cervical lymph node metastases from unknown primary. |
N Categories
| Stage | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed. |
| N0 | No regional lymph node metastasis. |
| N1 – Most sites (clinical) | Metastasis in a single ipsilateral lymph node, ≤3 cm in greatest dimension, ENE(-). |
| N2a – Most sites (clinical) | Metastasis in a single ipsilateral node >3 cm but ≤6 cm, ENE(-). |
| N2b – Most sites (clinical) | Metastases in multiple ipsilateral lymph nodes, none >6 cm, ENE(-). |
| N2c – Most sites (clinical) | Metastases in bilateral or contralateral lymph nodes, none >6 cm, ENE(-). |
| N3a – Most sites (clinical) | Metastasis in a lymph node >6 cm in greatest dimension, ENE(-). |
| N3b – Most sites (clinical) | Metastasis in any node(s) with clinically overt ENE(+). |
| N1 – HPV-mediated Oropharynx (clinical) | One or more ipsilateral lymph nodes, none >6 cm. |
| N2 – HPV-mediated Oropharynx (clinical) | Contralateral or bilateral lymph nodes, none >6 cm. |
| N3 – HPV-mediated Oropharynx (clinical) | Lymph node(s) >6 cm. |
| pN1 – Most sites (pathological) | Metastasis in a single ipsilateral lymph node, ≤3 cm, ENE(-). |
| pN2a – Most sites (pathological) | Metastasis in a single ipsilateral node ≤3 cm and ENE(+); or a single ipsilateral node >3 cm but ≤6 cm and ENE(-). |
| pN2b – Most sites (pathological) | Metastases in multiple ipsilateral nodes, none >6 cm, ENE(-). |
| pN2c – Most sites (pathological) | Metastases in bilateral or contralateral lymph node(s), none >6 cm, ENE(-). |
| pN3a – Most sites (pathological) | Metastasis in a lymph node >6 cm, ENE(-). |
| pN3b – Most sites (pathological) | Metastasis in a single ipsilateral node >3 cm and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+). |
| pN1 – HPV-mediated Oropharynx (pathological) | Metastasis in ≤4 lymph nodes. |
| pN2 – HPV-mediated Oropharynx (pathological) | Metastasis in >4 lymph nodes. |
| N1 – Nasopharynx (AJCC 9th ed., clinical) | Unilateral metastasis in cervical lymph node(s) and/or unilateral/bilateral retropharyngeal lymph node(s), ≤6 cm, above caudal border of cricoid, without advanced extranodal extension. |
| N2 – Nasopharynx (9th ed., clinical) | Bilateral metastasis in cervical lymph node(s), ≤6 cm, above caudal border of cricoid, without advanced extranodal extension. |
| N3 – Nasopharynx (9th ed., clinical) | Unilateral or bilateral metastasis in cervical lymph node(s) >6 cm, and/or extension below caudal border of cricoid, advanced radiologic extranodal extension with involvement of adjacent muscles, skin, and/or neurovascular bundle. |
| N1 – Mucosal Melanoma | Regional lymph node metastases present. (No further substaging.) |
| N0 – Mucosal Melanoma | No regional lymph node metastases. |
| N1 – Occult Primary (clinical) | Same as other sites: single ipsilateral node ≤3 cm, ENE(-). Refer to ST-15 for detailed classification. |
M Categories
| Stage | Description |
|---|---|
| M0 | No distant metastasis. |
| M1 | Distant metastasis present. |
| M1a – Nasopharynx (AJCC 9th ed.) | Distant metastasis with no more than 3 areas of cancer spread. |
| M1b – Nasopharynx (9th ed.) | Distant metastasis with more than 3 areas of spread. |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Stage 0 – Oral Cavity, Oropharynx, Larynx, Hypopharynx, Sinuses, Salivary Glands | Tis, N0, M0. | Carcinoma in situ, no invasion. | Excellent, >95% for most sites. | Curative; local excision or RT alone. |
| Stage I – Oral Cavity | T1, N0, M0. | Small tumor with DOI ≤5 mm, no nodal metastases. | Approximately 85-90%. | Curative; surgery (preferred) or RT. |
| Stage II – Oral Cavity | T2, N0, M0. | Tumor >2 cm but ≤4 cm with DOI ≤10 mm, or ≤2 cm with DOI >5 mm. | Approximately 75%. | Curative; surgery ± neck dissection or RT. |
| Stage III – Oral Cavity | T1–3, N1, M0 or T3, N0–1, M0. | Regional nodal involvement or larger primary. | Approximately 60%. | Curative; surgery + adjuvant RT or systemic therapy/RT. |
| Stage IVA – Oral Cavity | T1–3, N2, M0; or T4a, N0–2, M0. | Advanced local disease or multiple nodes. | Approximately 40-50%. | Curative; multimodality therapy. |
| Stage IVB – Oral Cavity | Any T, N3, M0; or T4b, any N, M0. | Very advanced local or nodal disease (carotid encasement, skull base, pterygoid plates). | Approximately 20-30%. | Curative intent with chemoradiation if resectable; otherwise palliative. |
| Stage IVC – Oral Cavity | Any T, any N, M1. | Distant metastases. | <10%. | Palliative; systemic therapy, RT for symptom control. |
| Stage I – HPV-mediated Oropharynx (clinical) | T0–2, N0–1, M0 (N1: ipsilateral nodes ≤6 cm). | Small primary with limited ipsilateral nodal disease. | 92-95%. | Curative; single modality (surgery or RT) or de-intensified chemoradiation in select cases. |
| Stage II – HPV-mediated Oropharynx (clinical) | T0–2, N2, M0; or T3, N0–2, M0. | Bilateral/contralateral nodes or larger primary. | 85-90%. | Curative; chemoradiation or surgery with adjuvant therapy. |
| Stage III – HPV-mediated Oropharynx (clinical) | T0–3, N3, M0; or T4, N0–3, M0. | Large nodes (>6 cm) or T4 primary. | 70-75%. | Curative; chemoradiation preferred; surgery for selected cases. |
| Stage IV – HPV-mediated Oropharynx (clinical) | Any T, any N, M1. | Distant metastases. | <30%. | Palliative; systemic therapy ± RT. |
| Stage IA – Nasopharynx (AJCC 9th ed.) | T1–2, N0, M0. | Early disease without nodal involvement. | >90%. | Curative; RT alone. |
| Stage IB – Nasopharynx (9th ed.) | T0–2, N1, M0. | Low-volume nodal disease. | 85-90%. | Curative; RT alone or with concurrent chemotherapy if high-risk features. |
| Stage II – Nasopharynx (9th ed.) | T0–2, N2, M0; or T3, N0–2, M0. | Bilateral nodes or advanced primary. | 75-85%. | Curative; concurrent chemoradiation ± induction chemotherapy. |
| Stage III – Nasopharynx (9th ed.) | T4, any N, M0; or any T, N3, M0. | Very advanced locoregional disease. | 60-75%. | Curative; induction chemotherapy followed by chemoradiation or chemoradiation alone. |
| Stage IVA – Nasopharynx (9th ed.) | Any T, any N, M1a (≤3 metastatic sites). | Oligometastatic disease. | Variable; 20-40% with aggressive therapy. | Potentially curative with systemic therapy + RT to primary and metastases. |
| Stage IVB – Nasopharynx (9th ed.) | Any T, any N, M1b (>3 metastatic sites). | Widespread metastases. | <10%. | Palliative; systemic therapy ± palliative RT. |
| Stage III – Occult Primary | T0, N1, M0. | Single node ≤3 cm, ENE(-). | 85-90% after neck dissection ± RT. | Curative. |
| Stage IVA – Occult Primary | T0, N2, M0. | Multiple or larger nodes without ENE. | 70-80%. | Curative; neck dissection + RT or chemoradiation. |
| Stage IVB – Occult Primary | T0, N3, M0. | Nodal disease >6 cm or ENE(+). | 50-60%. | Curative; chemoradiation (category 1 for ENE). |
| Stage IVC – Occult Primary | T0, any N, M1. | Distant metastases. | <10%. | Palliative. |
| Stage III – Mucosal Melanoma | T3, N0, M0. | Tumor limited to mucosa/soft tissue, no nodal disease. | Approximately 40-50%. | Curative; surgical resection ± postoperative RT. |
| Stage IVA – Mucosal Melanoma | T4a, N0, M0; or T3–4a, N1, M0. | Invasion of deep tissue or cartilage/bone (± nodes). | Approximately 20-30%. | Curative intent with surgery + RT ± systemic therapy. |
| Stage IVB – Mucosal Melanoma | T4b, any N, M0. | Skull base, brain, carotid involvement. | <10%. | Palliative; RT, systemic therapy, clinical trials. |
| Stage IVC – Mucosal Melanoma | Any T, any N, M1. | Distant metastases. | <5%. | Palliative systemic therapy. |
Staging Pearls
- HPV-positive oropharyngeal cancer has a separate staging system (AJCC 8th ed.) with better prognosis; T4b is not used and N staging is simplified based on size and laterality [ST-7].
- For oral cavity, depth of invasion (DOI) is integrated into T staging; a tumor >4 cm with DOI >10 mm is T4a [ST-1].
- Extranodal extension (ENE) is a critical risk factor and is incorporated into both clinical and pathological N staging for most sites; clinically overt ENE is designated cN3b [ST-1, ST-5].
- Nasopharyngeal carcinoma staging uses AJCC 9th edition with distinct N and M categories including retropharyngeal nodes and advanced radiologic ENE [ST-3].
- Mucosal melanoma staging begins at T3 (limited to mucosa) and T4a/b, reflecting its aggressive nature; there are no T1–2 categories [ST-19].
- Occult primary (cervical node metastasis without known primary) is staged as T0, N1–3, M0–1 using the cervical lymph node and unknown primary table [ST-15].
- Salivary gland tumors include extraparenchymal extension in T3 and above [ST-17].
- Pathological staging for HPV-positive oropharyngeal cancer uses node count (≤4 vs. >4) rather than size and ENE [ST-7].
- For laryngeal cancer, T3 includes vocal cord fixation and/or paraglottic space invasion; T4a requires through-cartilage invasion [ST-8].
- Sinonasal tumors have separate T staging for maxillary sinus and ethmoid sinus/nasal cavity [ST-11].
- Stage grouping for most sites uses AJCC 8th ed. prognostic stage groups; survival data are derived from older cohorts and may overestimate modern outcomes with improved treatment.
- cN0 neck assessment is challenging; FDG-PET/CT has a negative predictive value of 93% for nodal metastases [Discussion MS-8].
Management PrinciplesClick to collapse
The management of head and neck cancers requires a multidisciplinary approach integrating surgery, radiation oncology, medical oncology, and a wide range of support services. The NCCN guidelines emphasize that all patients need access to the full range of specialists with expertise in the comprehensive care of head and neck cancer for optimal treatment and follow-up [TEAM-1]. Outcomes are improved when patients are treated at high-volume centers [Discussion]. The choice of treatment modality—single-modality (surgery or RT) versus combined modality (e.g., surgery plus radiation or chemoradiation)—depends on the specific site of disease, histology, stage, and baseline comorbid conditions [Discussion]. Single-modality treatment is generally recommended for early-stage (stage I or II) HPV-unrelated cancers. Surgery is usually preferred for oral cavity and paranasal sinus cancers, while RT with or without chemotherapy is nearly always preferred for all stages of nasopharyngeal carcinoma and more advanced stages of HPV-related oropharyngeal cancer [Discussion]. For the approximately 60% of patients with locally or regionally advanced disease at diagnosis, combined modality therapy is generally recommended [Discussion]. Equipoise exists between the choices of surgery or RT as the primary treatment modality for stage I and II HPV-associated and -unassociated disease, often based on local institutional expertise and/or perceived relative morbidity [Discussion]. Participation in clinical trials is a preferred or recommended treatment option in many situations [Discussion]. The NCCN Panel has tried to create clinical trials with evidence-based practices while providing a statement of consensus as to the acceptable range of treatment options [Discussion]. Treatment should be individualized based on patient characteristics and goals of therapy [SYST-A 1 of 7]. Key components for all patients include smoking cessation counseling and alcohol use counseling, as well as screening for distress [OR-1, ORPH-1, HYPO-1, GLOT-1, SUPRA-1, NASO-1, ETHM-1, OCC-1, SALI-1, MM-1]. Fertility/reproductive counseling should be offered [OR-1, ORPH-1, HYPO-1, GLOT-1, SUPRA-1, NASO-1, ETHM-1, OCC-1, SALI-1, MM-1]. Screening for hepatitis B for patients undergoing cancer therapy is recommended [OR-1, ORPH-1, HYPO-1, GLOT-1, SUPRA-1, NASO-1, ETHM-1, OCC-1, SALI-1, MM-1].
Curative-intent treatment for newly diagnosed locoregionally confined disease
Patients with stage I-II (early-stage) disease who are candidates for single-modality therapy; patients with stage III-IV (locoregionally advanced) disease who are candidates for combined modality therapy
Early-stage: single-modality treatment with surgery or radiation therapy. Locoregionally advanced: combined modality therapy, typically surgery followed by risk-based adjuvant therapy (RT or systemic therapy/RT), or definitive concurrent systemic therapy/RT, or induction chemotherapy followed by RT or systemic therapy/RT. The specific approach depends on the primary site, HPV status (for oropharynx), and tumor extent.
Organ preservation or function preservation
Patients with laryngeal or hypopharyngeal cancer for whom total laryngectomy is indicated; patients with locally advanced oropharyngeal cancer where surgical morbidity is high
Concurrent systemic therapy/RT is the standard approach for larynx preservation in patients with advanced laryngeal cancer, based on the results of the RTOG 91-11 trial [Discussion]. For hypopharynx cancer, induction chemotherapy followed by definitive RT in responders is an alternative to laryngopharyngectomy [Discussion]. In oropharyngeal cancer, definitive RT or systemic therapy/RT is often preferred over upfront surgery for HPV-associated cT4 or cN3 disease to avoid triple modality therapy and additional treatment-induced morbidity [Discussion].
Palliative-intent treatment for incurable disease
Patients with metastatic (M1) disease at initial presentation, or with recurrent/persistent disease that is unresectable and not amenable to curative-intent reirradiation
Enrollment in a clinical trial is preferred. Systemic therapy, with the goal of palliation and survival prolongation, is the mainstay of treatment. Palliative RT may be used for symptom control (e.g., pain, bleeding, airway obstruction). Best supportive care is appropriate for patients with poor performance status [ADV-2, ADV-4]. For patients with newly diagnosed metastatic NPC, systemic therapy with or without consolidative locoregional RT may be considered for selected patients [NASO-3].
The comprehensive care of patients with head and neck cancers is complex and requires a multidisciplinary team. This team should include expertise from head and neck surgery, radiation oncology, medical oncology, diagnostic and interventional radiology, plastic and reconstructive surgery, specialized nursing care, dentistry/prosthodontics, physical medicine and rehabilitation (including therapy for lymphedema of the neck), speech and swallowing therapy, clinical social work, clinical nutrition, and pathology (including cytopathology) [TEAM-1]. Adjunctive services such as neurosurgery, ophthalmology, psychiatry, addiction services, audiology, palliative care, and pain management are also essential [TEAM-1]. Follow-up should be performed by a physician and other health care professionals with expertise in the comprehensive care and prevention of treatment sequelae and should include a comprehensive head and neck exam [TEAM-1]. It is critical that multidisciplinary evaluation and treatment be coordinated and integrated prospectively by all disciplines involved in patient care before the initiation of any treatment [SURG-A 1 of 9]. The initial evaluation and treatment planning requires a multidisciplinary team of health care providers with expertise in caring for such patients [Discussion].
Performance status (PS) is a critical determinant of treatment selection, particularly in the setting of very advanced (unresectable or metastatic) or recurrent/persistent disease. For newly diagnosed locoregionally advanced unresectable disease (T4b,N0-3 or unresectable primary or nodal disease or unfit for surgery), patients with PS 0-1 are candidates for aggressive concurrent systemic therapy/RT or induction systemic therapy followed by RT or systemic therapy/RT [ADV-1]. Patients with PS 2 may be treated with concurrent systemic therapy/RT (preferred) or RT alone. Patients with PS 3-4 should receive palliative RT, single-agent systemic therapy (for PS 3 only), or best supportive care [ADV-1]. For metastatic (M1) disease at initial presentation, patients with PS 0-1 can receive combination or single-agent systemic therapy, or locoregional treatment for selected patients with limited metastases. Patients with PS 2-3 should receive combination (PS 2 only) or single-agent systemic therapy, or best supportive care. Patients with PS 4 should receive best supportive care ± palliative RT [ADV-2]. The decision to treat with reirradiation should take into account surgical resectability, comorbidities, toxicity of previous treatment, organ dysfunction, and time since previous treatment; before curative intent reirradiation, the patient should have a reasonable ECOG PS of 0-1 [RAD-A 4 of 7]. For patients receiving or who have received checkpoint inhibitor therapies, ongoing monitoring for adverse reactions is required [FOLL-A 1 of 2].
Management PathwaysClick to collapse
Branching: Clinical T stage, Clinical N stage, Surgical candidacy, Depth of invasion
Branching: Clinical T stage, Clinical N stage, Resectability, PD-L1 CPS status, N stage for neoadjuvant pembrolizumab
Branching: HPV/p16 status, Clinical T stage, Clinical N stage, Surgical candidacy, PD-L1 CPS status
Branching: HPV/p16 status, Clinical T stage, Clinical N stage, Surgical candidacy, PD-L1 CPS status
Branching: HPV/p16 status, Clinical T stage, Clinical N stage, Surgical candidacy
Branching: HPV/p16 status, Clinical T stage, Clinical N stage, Surgical candidacy, Eligibility for concurrent systemic therapy/RT
Branching: EBV status, Clinical T stage, Clinical N stage, Presence of high-risk features
Branching: EBV status, Clinical staging, Suitability for cisplatin, Patient preference
Branching: EBV status, Performance status, Extent of metastatic disease (oligometastatic vs widely metastatic)
Branching: Clinical T and N stage, Suitability for conservation surgery, Pulmonary function status
Branching: Clinical T and N stage, Surgical candidacy, Response to induction chemotherapy, PD-L1 CPS status
Branching: T stage, Vocal cord mobility, Surgical candidacy, Pulmonary function
Branching: T stage, N stage, Larynx preservation desired, Patient preference, PD-L1 CPS status
Branching: Performance status, Prior RT status
Branching: Performance status, Extent of metastases (limited vs widespread), Primary site (NPC vs non-NPC)
Branching: Prior RT status, Resectability, Performance status, Interval from prior RT
Branching: Performance status, Extent of disease (distant metastases only vs locoregional + distant), Prior therapy
Branching: Histology, HPV/EBV status, Nodal level, Nodal stage, Resectability
Branching: Histology (benign vs malignant), Grade, T stage, Resectability
Branching: Histologic grade, Margin status, Perineural invasion, Lymph node metastases, T stage
Branching: Primary site, T stage, N stage
Pretreatment EvaluationClick to collapse
History and Physical Examination
Pathology and Biomarker Testing
Imaging
Functional and Supportive Assessments
Consultations
SurgeryClick to collapse
Surgery is a cornerstone of treatment for many head and neck cancers, particularly for resectable disease. For oral cavity and paranasal sinus cancers, surgery is usually preferred. For early-stage oropharyngeal, laryngeal, and hypopharyngeal cancers, surgery is an effective alternative to RT. For advanced disease, surgery is often combined with postoperative RT or systemic therapy/RT. The goal of surgery is complete tumor resection with histologic verification of tumor-free margins, maximizing survival while preserving form and function [Discussion, SURG-A]. Resection of the primary tumor should be planned based on the extent of the primary tumor as ascertained by clinical examination and careful interpretation of appropriate radiographic images. En bloc resection of the primary tumor should be attempted whenever feasible [SURG-A 3 of 9]. For patients undergoing an operation, the surgical procedure, margins, and reconstructive plan should be developed and designed to resect all gross tumors with adequate tumor-free surgical margins. The surgical procedure should rarely be modified based on any response observed as a result of prior therapy except in instances of tumor progression that mandate a more extensive procedure [SURG-A 1 of 9].
All patients should be evaluated by a head and neck surgical oncologist prior to treatment to ensure review of the adequacy of biopsy material, review staging and imaging to determine the extent of disease, exclude the presence of a synchronous primary tumor, assess current functional status, and evaluate for potential surgical options, including those applicable if initial nonsurgical treatment is unsuccessful [SURG-A 1 of 9].
Pre-treatment evaluation should include consultations with a medical oncologist, radiation oncologist, dentist or oral maxillofacial surgeon, speech-language pathologist, dietitian, and reconstructive surgeon as appropriate [SURG-A 1 of 9].
It is critical that multidisciplinary evaluation and treatment be coordinated and integrated prospectively by all disciplines involved in patient care before the initiation of any treatment [SURG-A 1 of 9].
An overarching goal of oncologic surgery is complete tumor resection with histologic verification of tumor-free margins. Tumor-free margins are an essential surgical strategy for diminishing the risk for local tumor recurrence. Conversely, positive margins increase the risk for local relapse and are an indication for postoperative adjuvant therapy [SURG-A 4 of 9].
Margins: Adequate resection is defined as clear resection margins with at least enough clearance from the gross tumor to obtain clear frozen section and permanent margins (often 1.0-1.5 cm of visible and palpable normal mucosa). For glottic cancers, a 1- to 2-mm margin is considered adequate. In transoral endoscopic and robotic approaches for oropharynx cancers, margins of 1.5-2.0 mm may be acceptable [SURG-A 4 of 9].
A positive margin is defined as carcinoma in situ or as invasive carcinoma at the margin of resection. If carcinoma in situ is present and if additional margins can be obtained, that is the favored approach. Carcinoma in situ should not be considered an indication for concurrent postoperative systemic therapy/RT [SURG-A 4 of 9].
Reconstruction of surgical defects should be performed using conventional techniques at the discretion of the surgeon. Primary closure is recommended when appropriate but should not be pursued at the expense of obtaining wide, tumor-free margins [SURG-A 4 of 9].
In oropharyngeal cancer cases (whether HPV positive or negative), treatment selection should favor usage of fewest modalities necessary in order to minimize treatment-related toxicity and preserve function. Avoid triple modality treatment when possible [SURG-A 3 of 9].
Procedures
Primary Tumor Resection (Oral Cavity)
Standard of care for resectable oral cavity cancers, including buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, and hard palate. For early-stage cancers, resection of primary ± neck dissection. For advanced cancers, resection of primary with ipsilateral or bilateral neck dissection [OR-2, OR-3].
Transoral Robotic Surgery (TORS) or Laser-Assisted Resection
Selected patients with accessible tumors of the oropharynx, larynx, and hypopharynx. Lung and hypopharynx.
Laryngectomy (Partial or Total)
Total laryngectomy: T3-4a laryngeal cancers, advanced hypopharyngeal cancers, recurrent/persistent disease after RT or systemic therapy/RT. Partial laryngectomy: selected T1-2, N0 glottic and supraglottic cancers.
Neck Dissection
Elective (for N0 disease at risk of occult metastasis), therapeutic (for clinically positive nodal disease). For N0 disease: selective neck dissection (oral cavity at least levels I-III; oropharynx at least levels II-IV; hypopharynx/larynx at least levels II-IV and level VI when appropriate). For N1-N2a-c: selective or comprehensive. For N3: comprehensive [SURG-A 6 of 9].
Salivary Gland Surgery (Parotidectomy, Submandibular Gland Excision)
Treatment of salivary gland tumors (parotid, submandibular, sublingual, minor salivary glands). Neck dissection for high-grade and/or T3-4 tumors [SALI-3].
Sentinel Lymph Node Biopsy (SLNB)
Early (T1 or T2) oral cavity squamous cell carcinoma, particularly oral tongue. Also considered for high-risk lip cancers. For oral cavity cancer, SLN biopsy is an alternative to elective neck dissection [SURG-A 7 of 9].
Radiation TherapyClick to collapse
Radiation therapy is a critical modality in the treatment of head and neck cancers, used as definitive treatment (RT alone or concurrent systemic therapy/RT), adjuvant therapy (postoperative RT or systemic therapy/RT), or palliative therapy. For nasopharyngeal carcinoma, RT (with or without chemotherapy) is nearly always preferred for all stages. For early-stage laryngeal and oropharyngeal cancers, RT is an effective alternative to surgery. IMRT is the preferred radiation modality for most head and neck cancers due to its ability to reduce dose to critical structures and decrease long-term toxicities such as xerostomia. Proton therapy is an area of active investigation and may be considered when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes [RAD-A 1 of 7, ORPH-A 1 of 2, OR-A 1 of 2, HYPO-A 1 of 2, GLOT-A 1 of 2, SUPRA-A 1 of 2, NASO-A, ETHM-A, MAXI-A, OCC-A 1 of 2, SALI-A, MM-A].
Principles
- All patients should be evaluated by a radiation oncologist prior to treatment to review staging and imaging to determine the extent of disease, exclude the presence of a synchronous primary tumor, assess functional status, and evaluate for potential RT options [RAD-A 1 of 7].
- Target delineation and optimal dose distribution require experience in head and neck imaging and a thorough understanding of patterns of disease spread. Standards for target definition, dose specification, fractionation (with and without concurrent chemotherapy), and normal tissue constraints are still evolving [RAD-A 1 of 7].
- IMRT (preferred) or other conformal techniques (helical tomotherapy, VMAT, and proton beam therapy) may be used as appropriate depending on the stage, tumor location, physician training/experience, and available physics support [RAD-A 1 of 7].
- Advanced RT technologies such as IMRT, tomotherapy, VMAT, IGRT, and PBT may offer clinically relevant advantages in specific instances to spare important OARs, such as the brain, brain stem, cochlea, semicircular canals, optic chiasm and cranial nerves, retina, lacrimal glands, cornea, spinal cord, brachial plexus, mucosa, salivary glands, bone (skull base and mandible), pharyngeal constrictors, larynx, and esophagus, and decrease the risk for late, normal tissue damage while still achieving the primary goal of local tumor control [RAD-A 1 of 7].
- Since the advantages of these techniques include tightly conformal doses and steep gradients next to normal tissues, target definition and delineation and treatment delivery verification require careful monitoring to avoid the risk of tumor geographic miss and subsequent decrease in local tumor control [RAD-A 1 of 7].
- Image guidance is required to provide assurance of accurate daily delivery. Anatomical changes including rapidly shrinking tumors, changes in air cavities, or significant weight loss may necessitate repeat diagnostic imaging and replanning (adaptive treatment) [RAD-A 1 of 7].
- The preferred interval between resection and initiation of postoperative RT is ≤6 weeks [OR-A 2 of 2, ORPH-A 2 of 2, HYPO-A 2 of 2, GLOT-A 2 of 2, SUPRA-A 2 of 2, ETHM-A, MAXI-A, ADV-A 2 of 2, OCC-A 2 of 2, SALI-A, MM-A].
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indication |
|---|---|---|---|---|---|
| High-risk PTV (Gross Disease) - Definitive RT | 66-70 Gy | 2.0 Gy/fraction (or 2.2 Gy/fraction for 66 Gy) | 33-35 fractions | Daily Monday-Friday in 6-7 weeks | Definitive treatment for primary tumor and involved lymph nodes for most head and neck subsites [OR-A 1 of 2, ORPH-A 1 of 2, HYPO-A 1 of 2, GLOT-A 1 of 2, SUPRA-A 1 of 2, NASO-A, ETHM-A, MAXI-A, OCC-A 1 of 2] |
| High-risk PTV (Gross Disease) - Concomitant Boost Accelerated RT | 72 Gy | 1.8 Gy/fraction (large field) + 1.5 Gy boost as second daily fraction during last 12 treatment days | 30 fractions (large field) + 12 fractions (boost) | 6 weeks | Definitive treatment for head and neck cancers, particularly when using accelerated fractionation [OR-A 1 of 2, ORPH-A 1 of 2, HYPO-A 1 of 2, GLOT-A 1 of 2, SUPRA-A 1 of 2, ETHM-A, MAXI-A, ADV-A 2 of 2] |
| High-risk PTV (Gross Disease) - Hyperfractionation | 81.6 Gy (up to 74.4-81.6 Gy for T2,N0-1 oropharynx) | 1.2 Gy/fraction | 68 fractions (or 62-68 fractions for oropharynx T2,N0-1) | Twice daily, 6-7 weeks | Definitive treatment for head and neck cancers, particularly when tumor is abutting brain or optic structures, or for improved locoregional control [OR-A 1 of 2, ORPH-A 1 of 2, HYPO-A 1 of 2, GLOT-A 1 of 2, SUPRA-A 1 of 2, ETHM-A, MAXI-A, ADV-A 2 of 2] |
| High-risk PTV (Gross Disease) - Alternative | 69.96 Gy | 2.12 Gy/fraction | 33 fractions | Daily Monday-Friday in 6-7 weeks | Alternative definitive fractionation for oropharynx, hypopharynx, and nasopharynx cancers [ORPH-A 1 of 2, HYPO-A 1 of 2, NASO-A] |
| T1,N0 Glottic Larynx - Accelerated | 63 Gy (preferred) to 66 Gy | 2.25 Gy/fraction (preferred) to 2.0 Gy/fraction | 28 fractions for 63 Gy (preferred), 33 fractions for 66 Gy | Daily Monday-Friday | Definitive RT for T1,N0 glottic larynx cancer. The 63 Gy schedule is associated with better 5-year local control [GLOT-A 1 of 2] |
| T1,N0 Glottic Larynx - Hypofractionation | 50 Gy to 52 Gy | 3.12 Gy/fraction to 3.28 Gy/fraction | 16 fractions for 50 Gy, 15-16 fractions for 52 Gy | Daily Monday-Friday | Alternative for patients with comorbidities or travel logistics or who are older adults [GLOT-A 1 of 2] |
| Low to Intermediate Risk PTV (Subclinical Disease) - Definitive or Postoperative | 44-50 Gy (sequential IMRT) or 54-63 Gy (SIB IMRT) | 1.6-2.0 Gy/fraction (dependent on technique) | Variable based on total dose and fractionation | Daily Monday-Friday | Elective irradiation of sites of suspected subclinical spread for all subsites [OR-A 1 of 2, ORPH-A 1 of 2, HYPO-A 1 of 2, GLOT-A 1 of 2, SUPRA-A 1 of 2, NASO-A, ETHM-A, MAXI-A, OCC-A 1 of 2, SALI-A] |
| Postoperative High-Risk PTV | 60-66 Gy | 2.0 Gy/fraction | 30-33 fractions | Daily Monday-Friday in 6-6.5 weeks | Adjuvant treatment for adverse pathologic features such as positive margins or extranodal extension [OR-A 2 of 2, ORPH-A 2 of 2, HYPO-A 2 of 2, GLOT-A 2 of 2, SUPRA-A 2 of 2, ETHM-A, MAXI-A, ADV-A 2 of 2, OCC-A 2 of 2, SALI-A] |
| Reirradiation - Conventional Fractionation Postoperative | 56-60 Gy | 1.8-2 Gy/fraction | 28-33 fractions | Daily Monday-Friday | Reirradiation in the postoperative setting for recurrent disease [RAD-A 4 of 7] |
| Reirradiation - Conventional Fractionation Definitive | 66-70 Gy | 1.8-2 Gy/fraction | 33-39 fractions | Daily Monday-Friday | Reirradiation with curative intent for unresectable recurrent disease [RAD-A 4 of 7] |
| Reirradiation - Hyperfractionation for Locally Advanced Nasopharyngeal Carcinoma | 64.8 Gy | 1.2 Gy/fraction | 54 fractions | Twice daily, with an irradiation interval of 6-8 hours | Reirradiation for locally advanced recurrent nasopharyngeal carcinoma, associated with improved 3-year OS compared to mild hypofractionation [RAD-A 4 of 7] |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| Definitive RT Alone | 66-70 Gy (2.0 Gy/fraction) to high-risk PTV; 44-50 Gy (sequential IMRT) or 54-63 Gy (SIB) to low/intermediate-risk PTV. Altered fractionation (hyperfractionation, accelerated fractionation) may be used for improved locoregional control, particularly in the RT-alone setting [OR-A 1 of 2, ORPH-A 1 of 2, HYPO-A 1 of 2, GLOT-A 1 of 2, SUPRA-A 1 of 2, NASO-A, ETHM-A, MAXI-A, OCC-A 1 of 2]. | None | Definitive treatment for early-stage cancers (T1-2,N0 for oral cavity, oropharynx, larynx, hypopharynx) or for patients who are not candidates for or decline systemic therapy. Also for T1,N0 nasopharyngeal cancer [OR-2, ORPH-2, ORPHPV-1, HYPO-2, GLOT-2, SUPRA-2, NASO-2]. | RTOG 90-03: Hyperfractionation and accelerated fractionation with concomitant boost showed improved locoregional control and DFS compared to standard fractionation in the RT-alone setting [Discussion]. MARCH meta-analysis: absolute survival benefit for altered fractionation of 3.4% at 5 years (HR, 0.92; 95% CI, 0.86-0.97; P = .003) [Discussion]. | Xerostomia, mucositis, dysphagia, dermatitis, fatigue, taste alteration, lymphedema, fibrosis, osteoradionecrosis, hypothyroidism, carotid stenosis, trismus. |
| Concurrent Systemic Therapy/RT (Definitive) | High-risk PTV: Typically 70 Gy (2.0 Gy/fraction). Low to intermediate risk: 44-50 Gy (sequential IMRT) or 54-63 Gy (SIB). Conventional fractionation is most commonly used with concurrent systemic therapy [OR-A 1 of 2, ORPH-A 1 of 2, HYPO-A 1 of 2, GLOT-A 1 of 2, SUPRA-A 1 of 2, NASO-A, ETHM-A, MAXI-A, OCC-A 1 of 2]. | High-dose cisplatin 100 mg/m2 every 3 weeks (preferred, category 1). Other options: weekly cisplatin 40 mg/m2, carboplatin/fluorouracil (category 1), carboplatin/paclitaxel (category 2B), docetaxel (for cisplatin-ineligible patients), cetuximab (category 2B) [SYST-A 2 of 7]. | Standard of care for locoregionally advanced, unresectable head and neck cancers (PS 0-1), and for larynx preservation in advanced laryngeal cancer. Also for locally advanced oropharyngeal cancer (HPV-positive and HPV-negative) and for many patients with locoregionally advanced disease [OR-3, ORPH-3, ORPH-4, ORPHPV-3, ORPHPV-4, HYPO-3, HYPO-5, GLOT-3, GLOT-4, SUPRA-3, SUPRA-5, SUPRA-6, ADV-1]. | Intergroup 0099 (NPC), RTOG 0129 (oropharynx), RTOG 91-11 (larynx). Meta-analyses show significantly improved OS, DFS, and locoregional control with concurrent systemic therapy/RT compared to RT alone [Discussion]. | Significant increased acute toxicity (mucositis, dermatitis, dysphagia, weight loss, hematologic toxicity) compared to RT alone. High-dose cisplatin adds nephrotoxicity, ototoxicity, neuropathy. Altered fractionation with concurrent chemotherapy offers no clear advantage and increases toxicity. |
| Postoperative RT or Systemic Therapy/RT | High-risk PTV: 60-66 Gy (2.0 Gy/fraction). Low/intermediate-risk PTV: 44-50 Gy (sequential IMRT) or 54-63 Gy (SIB). Preferred interval between resection and initiation is ≤6 weeks [OR-A 2 of 2, ORPH-A 2 of 2, HYPO-A 2 of 2, GLOT-A 2 of 2, SUPRA-A 2 of 2, ETHM-A, MAXI-A, ADV-A 2 of 2, OCC-A 2 of 2, SALI-A]. | Cisplatin (category 1 for high-risk non-oropharyngeal cancers). Systemic therapy/RT is added for high-risk features (extranodal extension and/or positive margins) [SYST-A 3 of 7]. For oropharynx cancers, the addition of chemotherapy is based on risk stratification [ORPH-A 2 of 2]. | Postoperative treatment for patients with adverse pathologic features such as advanced T stage, close/positive margins, extranodal extension, multiple positive nodes, perineural/lymphovascular invasion. Concurrent systemic therapy/RT is indicated for extranodal extension and/or positive margins (category 1 for non-oropharyngeal sites) [OR-3, ORPH-2, ORPH-3, ORPH-4, HYPO-2, HYPO-3, HYPO-5, GLOT-2, GLOT-3, GLOT-4, SUPRA-2, SUPRA-3, SUPRA-5, SUPRA-6]. | RTOG 9501 and EORTC 22931: Established benefit of adding cisplatin to postoperative RT for patients with positive margins or extranodal extension. Combined analysis showed survival advantage for patients with these high-risk features [Discussion]. | Similar to definitive chemoradiation, but may be compounded by surgical morbidity. Late effects include fibrosis, lymphedema, xerostomia, dysphagia, osteoradionecrosis, hypothyroidism. |
| Reirradiation | Conventional fractionation: 56-60 Gy (postoperative) or 66-70 Gy (definitive) at 1.8-2 Gy/fraction. Hyperfractionation for locally advanced recurrent NPC: 64.8 Gy in 54 fractions twice daily. SBRT: 35-44 Gy in 5 fractions [RAD-A 4 of 7]. | Cisplatin (preferred), or carboplatin, cetuximab, or docetaxel (all category 2B) [SYST-A 3 of 7]. | Locoregional recurrent or persistent disease or second primary after prior RT. Careful patient selection: should be ≥6 months from prior RT, reasonable ECOG PS 0-1. Patients who are >2 years from prior radiation, have surgery to remove gross disease prior to reirradiation, and are free of organ dysfunction have better outcomes [RAD-A 4 of 7]. | Randomized phase III multicenter trial in France (N=130): reirradiation combined with systemic therapy after resected recurrence improved DFS compared to surgery alone (HR, 1.68; 95% CI, 1.13-2.50; P = .01) [Discussion]. | Considerably increased toxicity. Grade 3-4 acute mucositis/pharyngitis in 28% in historical study. Risk of myelopathy, osteoradionecrosis, soft tissue necrosis, fistula, carotid blowout. PBT may reduce toxicity [RAD-A 4 of 7]. |
| Palliative RT | Several recommended regimens: 50 Gy in 20 fractions; 37.5 Gy in 15 fractions (can add 5 more to 50 Gy); 30 Gy in 10 fractions; 30 Gy in 5 fractions (give 2 fractions/wk with ≥3 days apart); 44.4 Gy in 12 fractions (3 cycles, 2 fractions 6 hours apart for 2 days in a row, must exclude spinal cord after second cycle) [RAD-A 3 of 7]. | May be used but is not standard for palliative intent. | Palliation for patients with incurable locally advanced or metastatic disease when curative-intent treatment is not appropriate. Should be considered for relief or prevention of locoregional symptoms if RT toxicities are acceptable. Careful evaluation of PS, treatment tolerance, tumor response, and/or any systemic progression is needed [RAD-A 3 of 7]. | None | Should be minimized as treatment is for palliation. Fatigue, mucositis, dermatitis, dysphagia. |
Systemic TherapyClick to collapse
Systemic therapy plays a critical role in the management of head and neck cancers, particularly for locoregionally advanced disease (concurrent with RT or as induction/adjuvant therapy), and for recurrent or metastatic disease. The choice of systemic therapy should be individualized based on patient characteristics and goals of therapy [SYST-A 1 of 7]. For locoregionally advanced squamous cell carcinoma of the head and neck, the preferred chemoradiotherapy approach for fit patients remains concurrent cisplatin and radiotherapy. Cisplatin-based induction chemotherapy can be used, followed by radiation-based locoregional treatment, but an improvement in OS with the incorporation of induction chemotherapy compared to proceeding directly to state-of-the-art concurrent chemoradiation has not been established in randomized studies [SYST-A 1 of 7]. For recurrent or metastatic disease, immunotherapy (pembrolizumab or nivolumab) has become a cornerstone of treatment, with platinum-based chemotherapy combinations offering additional options. The NCCN guidelines emphasize that multigene panel testing and biomarker testing (including PD-L1, MSI, MMR, TMB, HER2, FGFR) may be considered to guide patient treatment options, including clinical trials [SYST-A 1 of 7]. Nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab, but is not approved for concurrent use with IV ipilimumab. Pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection may be substituted for IV pembrolizumab [SYST-A 1 of 7].
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Assessment of Treatment Response after Systemic Therapy/RT or RT
Timing
Response assessment is conducted at specific intervals following definitive treatment with systemic therapy/RT or RT alone. The optimal timing is crucial to minimize false-positive results. For FDG-PET/CT, the first scan should be performed at a minimum of 12 weeks after treatment to reduce the false-positive rate. For CT or MRI, imaging is typically obtained at 8-12 weeks, but early scans before 8 weeks are associated with significant false-positive rates and should be avoided in the absence of signs of recurrence or progression. The optimal timing of PET scans after radiation treatment appears to be at 3 months [FOLL-A 2 of 2, IMG-A 3 of 4, Discussion].
Response Logic
-
After systemic therapy/RT or RT, a clinical assessment is performed at 4-8 weeks as appropriate [FOLL-A 2 of 2].
-
If there is residual primary, persistent disease, or progression, the extent of disease or distant metastases should be assessed with CT (with contrast) or MRI with and without contrast, or FDG-PET/CT [FOLL-A 2 of 2].
-
If a response is observed, the extent of disease or distant metastases is assessed with FDG-PET/CT at a minimum of 12 weeks (preferred) or CT (with contrast) of primary and neck and/or MRI with and without contrast at 8-12 weeks [FOLL-A 2 of 2].
-
If imaging is negative (no or low-grade uptake, felt not suspicious for disease), observation is recommended. A second negative PET performed at 6 months after this baseline has a high negative prediction value, and radiologic assessment can be suspended for patients with asymptomatic disease at this time point [FOLL-A 2 of 2, IMG-A 3 of 4].
-
If imaging is positive (PET suspicious for disease), a biopsy is recommended to confirm residual or persistent disease or progression [FOLL-A 2 of 2].
-
If imaging is equivocal, a repeat FDG-PET/CT at 3-6 months may help identify patients who can be safely observed without surgery. Observation or repeat imaging is recommended [FOLL-A 2 of 2].
-
For patients with complete clinical response (no visible or palpable evidence of residual disease and no concerning findings on CT or MRI), observation is recommended. If complete response is achieved, the Panel recommends observing the patient [Discussion].
-
For patients with histologically confirmed residual or persistent disease or progression, surgical resection is indicated if feasible (resection of primary and/or neck dissection). If unresectable, patients should receive systemic therapy and/or RT as described for recurrent or persistent disease (ADV-3) [FOLL-A 2 of 2].
Imaging Recommendations
-
FDG-PET/CT is the preferred imaging modality for post-treatment response assessment due to its high sensitivity and negative predictive value. It should be performed within 3-6 months of definitive radiation, systemic therapy/RT, surgery, or adjuvant RT [IMG-A 3 of 4].
-
Early FDG-PET/CT scans before 12 weeks are associated with significant false-positive rates and should be avoided in the absence of signs of recurrence or progression [IMG-A 3 of 4].
-
CT (with contrast) or MRI (with and without contrast) of the primary and neck is an alternative to PET/CT for response assessment. CT or MRI may be obtained at 8-12 weeks post-treatment [FOLL-A 2 of 2].
-
In cases of concern for incomplete non-response or disease progression, a CT or MRI scan may be obtained much earlier, such as 4-8 weeks post-treatment or even immediately based on the specific clinical situation. Ultrasound of the neck for targeted sampling of any suspicious tissues may also be helpful [IMG-A 3 of 4].
-
Early CT/MRI scans before 8 weeks are associated with significant false-positive rates and should be avoided in the absence of signs of recurrence or progression [IMG-A 3 of 4].
-
For patients with locoregionally advanced disease who have undergone surgery, postoperative imaging is recommended for those who show signs of early recurrence or who are at high risk of early recurrence prior to starting adjuvant postoperative therapy. CT and/or MRI should be obtained within 3-4 months after surgical treatment [IMG-A 3 of 4].
-
For long-term surveillance (≥6 months to 5 years post-treatment), there are no consensus guidelines on the frequency and modality of routine post-treatment imaging in the asymptomatic patient. If an FDG-PET/CT at 3 months post-treatment is negative, there are no data to support substantial benefit for further routine imaging in an asymptomatic patient with negative exam. A tailored approach to surveillance with attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate [IMG-A 4 of 4].
Biopsy Or Salvage Logic
-
Any patient with residual disease after RT-based treatment should be considered for surgical resection for refractory disease, including a neck dissection if indicated [FOLL-A 2 of 2, Discussion].
-
If the residual, persistent, or progressing disease is histologically confirmed and unresectable, patients should receive systemic therapy and/or RT as described for recurrent or persistent disease (ADV-3) [FOLL-A 2 of 2].
-
For patients with equivocal PET/CT scan results in the neck, a prospective study suggests that a repeat PET/CT scan 4 to 6 weeks later may help identify those patients who can be safely observed without surgery to the neck. These patients may also continue to be observed if the clinical examination is reassuring [Discussion].
-
In patients with a clinically negative neck (no visible or palpable evidence of residual disease and no concerning findings on CT or MRI), PET/CT is associated with NPVs ranging from 97% to 100%. The Panel recommends observing the patient [Discussion].
-
Salvage surgery for recurrent or persistent disease is associated with increased risk of complications, particularly after prior RT. Patients may require microvascular free tissue transfer for reconstruction. Despite risks, surgery for relapsed/refractory disease has demonstrated favorable survival outcomes [Discussion].
-
A multidisciplinary evaluation prior to salvage surgery is critical to guide treatment options with the goal of maximizing survival with preservation of form and function [Discussion].
SurveillanceClick to collapse
Clinical Follow Up Schedule
- Year 1: Every 1–3 months (head and neck exam including mirror/fiberoptic).
- Year 2: Every 2–6 months.
- Years 3–5: Every 4–8 months.
- >5 years: Every 12 months.
- Frequency depends on risk of relapse, second primaries, and treatment sequelae. All patients who currently smoke should be advised to quit; former smokers should remain abstinent.
Imaging Strategy
- Baseline post-treatment imaging: For locoregionally advanced disease, CT/MRI is recommended within 3–4 months after surgery to establish a new baseline. FDG-PET/CT should be performed within 3–6 months after definitive RT or systemic therapy/RT (optimally at 3 months) to assess treatment response [Cheung 2016, Heineman 2017].
- Early imaging (before 8 weeks for CT/MRI, before 12 weeks for PET/CT) is associated with significant false-positive rates and should be avoided unless signs of recurrence or progression are present [IMG-A 3 of 4].
- If FDG-PET/CT is negative at 3 months, further routine imaging in asymptomatic patients has limited benefit; a tailored approach based on tumor type, stage, symptoms, and exam changes is appropriate.
- Annual imaging (CT/MRI) may be indicated for areas inaccessible to clinical examination (e.g., deep-seated skull base, areas obscured by treatment change).
- For patients with high smoking history, annual low-dose chest CT may be considered for lung cancer screening.
- Ultrasound of the neck is a safe, inexpensive, and accurate tool for nodal surveillance [Paleri 2016].
- If clinical concern for metastatic disease is confined to a specific anatomical area, directed CT or MRI may be used.
- For patients receiving immunotherapy, imaging every 2–3 cycles in the recurrent/metastatic setting is recommended [SYST-A 1 of 7].
Laboratory Monitoring
- TSH every 6–12 months if neck irradiation and/or partial thyroidectomy.
- For skull base RT: annual AM cortisol, GH, free T4, prolactin, LH/FSH, ACTH, TSH, total and bioavailable testosterone (category 2B) [VanKoevering 2020].
- Consider EBV DNA monitoring for EBER+ nasopharyngeal cancer (category 2B).
- For patients receiving cisplatin: routine monitoring of creatinine, magnesium, and audiogram as clinically indicated.
- Hepatitis B screening for all patients undergoing cancer therapy; chronic HBV carriers should receive antiviral prophylaxis during and for at least 12 months after anticancer therapy.
Supportive Follow Up
- Speech/hearing and swallowing evaluation and rehabilitation as clinically indicated.
- Nutritional evaluation and rehabilitation until nutritional status is stabilized.
- Ongoing surveillance for depression (NCCN Guidelines for Distress Management).
- Smoking cessation and alcohol counseling as clinically indicated.
- Lymphedema evaluation and rehabilitation as indicated (see NCCN Guidelines for Survivorship, SLYMPH-A).
- For patients receiving or who received checkpoint inhibitor therapies, monitor for ongoing adverse reactions (see NCCN Guidelines for Management of Immunotherapy-Related Toxicities).
- Integration of survivorship care and care plan within 1 year, complementary to ongoing head and neck oncology follow-up [Cohen 2016].
- Additional health monitoring and immunizations under primary care physician.
ComplicationsClick to collapse
Disease-Related
| Complication | Management |
|---|---|
| Dysphagia and aspiration | Swallowing evaluation and therapy; feeding tube placement if severe; speech-language pathology involvement. |
| Airway obstruction | Tracheostomy or tumor debulking as indicated. |
| Pain | Multimodal analgesia including opioids; referral to pain management and palliative care. |
| Hemorrhage (from tumor erosion) | Urgent evaluation; possible embolization or surgical intervention. |
| Malnutrition and weight loss | Nutritional assessment and support; enteral feeding via NG or PEG tube per NUTR-A guidelines. |
| Speech and voice changes | Speech-language therapy; possible prosthetic or surgical voice restoration. |
Supportive CareClick to collapse
Most patients with head and neck cancer experience weight loss and nutritional compromise due to disease, health behaviors, and treatment-related toxicities. The NCCN Panel emphasizes that a registered dietitian and speech-language/swallowing therapist should be part of the multidisciplinary team throughout the continuum of care [NUTR-A]. Close monitoring of nutritional status is recommended for patients with significant weight loss (≥5% in 1 month or ≥10% in 6 months) or difficulty swallowing. All patients should receive nutrition counseling and interventions as indicated, including feeding tubes (NG, NJ, PEG, PEJ) or IV nutrition if enteral support is not feasible. Routine dental evaluation and management is essential to prevent osteoradionecrosis and dental caries. Smoking cessation and alcohol counseling are recommended. Screening for distress using the NCCN Distress Thermometer (including social determinants of health) is advised. The Panel also recommends referring to NCCN Guidelines for Palliative Care, Adult Cancer Pain, and Survivorship as needed.
All patients should be evaluated for nutritional risk and receive counseling by a registered dietitian. Prophylactic feeding tube placement is not recommended for patients with good performance status and without significant pretreatment weight loss, airway obstruction, or severe dysphagia. Prophylactic placement should be strongly considered for those with severe weight loss (≥5% in 1 month, ≥10% in 6 months), ongoing dehydration/dysphagia, significant comorbidities, severe aspiration, or anticipated long-term swallowing disorders. For patients without prophylactic tubes, caloric intake, side effects, and weight should be monitored weekly during treatment. Reactive feeding tube placement is indicated if two or more criteria are met: inadequate intake (<60% energy expenditure) for >10 days, weight loss ≥5% in 1 month, severe mucositis/dysphagia/aspiration, or age >60 years [NUTR-A 2 of 3, Talwar 2016, Sachdev 2015]. To maintain swallowing function, patients with feeding tubes should be encouraged to continue oral intake if able to swallow safely.
The NCCN Guidelines do not provide a specific antiemetic protocol for head and neck cancer; however, cisplatin-based chemotherapy is highly emetogenic and requires a 3- or 4-drug antiemetic regimen (NK1 receptor antagonist, 5-HT3 antagonist, dexamethasone, ± olanzapine) per supportive care standards. The Panel refers clinicians to the NCCN Guidelines for Antiemesis (available at www.NCCN.org).
The NCCN Guidelines for Head and Neck Cancers do not provide separate G-CSF guidance; clinicians should refer to the NCCN Guidelines for Myeloid Growth Factors for management of febrile neutropenia risk during chemotherapy regimens such as TPF or cisplatin-based therapy.
No specific VTE prophylaxis recommendations are provided in the head and neck guideline. The Panel acknowledges that patients with cancer undergoing surgery or systemic therapy are at increased risk; refer to the NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease.
Pain from oral mucositis is common during RT, especially with concurrent chemotherapy. The Panel recommends considering pregabalin (category 2B), gabapentin, doxepin mouthwash, or diphenhydramine/lidocaine/antacid mouthwash as clinically indicated [Alliance A221304 trial, Sio 2019; Lefebvre 2021; Bar Ad 2010]. Prophylactic gabapentin at high doses (up to 3600 mg daily) has been associated with reduced opioid use and longer time to first opioid [Ma 2022]. Referral to dentistry/oral medicine and/or supportive medicine is recommended for assistance in functional assessments and symptom palliation. For neuropathic pain related to RT, pregabalin may be effective [Jiang 2019].
Screening for distress is recommended using the NCCN Distress Thermometer and Problem List, which includes social determinants of health [DIS-A]. Depression assessment and management should follow NCCN Guidelines for Distress Management. Support services should include clinical social work, psychiatry, addiction services, and care coordination. The Panel emphasizes that patients should be fully involved in shared decision-making.
A comprehensive dental/oral evaluation before RT is essential. Goals include patient education, elimination of potential sources of infection (with extractions at least 2 weeks before RT), treatment of active caries and periodontal disease, and prescription of high-potency topical fluoride for daily long-term use (1.1% NaF gel, SNF2 gel, or fluoride varnish three times per year) [DENT-A]. Salivary stimulation with gustatory stimulants (xylitol gum, sorbitol/malic acid lozenges) or cholinergic agonists (pilocarpine, cevimeline) is recommended for xerostomia. Salivary substitutes (gels with lysozyme, lactoferrin, peroxidase, supersaturated calcium phosphate) and alcohol-free mouthwash (stabilized 0.1% chlorine dioxide) may be used. Candidiasis should be prevented/treated with topical antifungal lozenges (sugar-free preferred) or systemic antifungals if refractory. Dental recall visits should be at least every 6 months, more frequently for high-risk patients.
PrognosisClick to collapse
The overall prognosis for head and neck cancers varies widely by primary site, stage, HPV status, and patient comorbidities. In 2026, an estimated 72,770 new cases and 17,110 deaths from oral cavity, pharyngeal, and laryngeal cancers are projected in the United States [Siegel 2026]. Squamous cell carcinomas account for >90% of these tumors. Tobacco and alcohol use are the predominant etiologic factors for HPV-unrelated cancers, while HPV infection (primarily HPV16) drives a growing proportion of oropharyngeal cancers, particularly among younger individuals [Gillison 2000, Chaturvedi 2011]. Patients with HPV-positive oropharyngeal cancer have significantly better outcomes than those with HPV-negative disease. For example, an individual patient data analysis (HNCIG-EPIC-OPC) reported 5-year overall survival (OS) of 81.1% for p16+/HPV+ oropharyngeal cancer versus 40.4% for p16-/HPV- disease [Mehanna 2023]. Stage at diagnosis is a strong predictor: early-stage (I–II) HPV-unrelated cancers (about 30% of patients) have high cure rates with single-modality therapy, while locally advanced (Stage III–IVA) disease (≈60%) requires multimodality treatment and carries a less favorable prognosis. Distant metastases at presentation (≈10%) confer the worst outcomes. In the nasopharynx, the Intergroup 0099 trial demonstrated 5-year OS of 70% with concurrent chemoradiation versus 59% with radiotherapy alone [Al-Sarraf 1998]. For laryngeal cancer, early glottic primaries have an 80–90% cure rate, whereas advanced stage III–IV disease has poorer survival. The AJCC 9th edition staging system now recognizes the distinct prognosis of HPV-related oropharyngeal cancer with separate staging criteria [Evans 2025].
By Stage
| Stage | Five Yr Survival | Context |
|---|---|---|
| Stage I (HPV-unrelated oral cavity/oropharynx/larynx) | Approximately 80–90% for most sites, but varies by site and specific T/N classification. | Early-stage disease (T1–2 N0) is often curable with surgery or radiotherapy alone. For glottic larynx, T1 N0 has >90% local control with radiotherapy or endoscopic resection [Yamazaki 2006]. |
| Stage II (HPV-unrelated) | Typically 60–80% depending on site and depth of invasion. | For oral cavity, T2 N0 with depth of invasion >5 mm may be upstaged to higher risk in AJCC 8th edition. Surgery with or without adjuvant therapy yields good outcomes. |
| Stage III–IVA (locally advanced, HPV-unrelated) | Approximately 40–60% across sites, with significant variation by T/N category and presence of extranodal extension. | Concurrent chemoradiation (cisplatin + RT) or surgery with adjuvant therapy is standard. The MACH-NC meta-analysis showed an absolute survival benefit of 6.5% at 5 years with concurrent chemoradiation versus RT alone [Pignon 2000, 2007]. |
| Stage IVB–C (unresectable or metastatic) | <20% for unresectable disease; metastatic disease median OS approximately 10–13 months with modern therapy. | For recurrent/metastatic disease, first-line pembrolizumab-based regimens (KEYNOTE-048) improved OS compared to EXTREME: median OS 13.0 months for pembrolizumab + chemotherapy vs 10.7 months (HR 0.77) [Burtness 2019]. |
| HPV-positive oropharyngeal cancer (AJCC 8th edition clinical stage I–III) | Stage I: >90%; Stage II: approximately 80–90%; Stage III: approximately 70–80%. | The ICON-S staging system (O'Sullivan 2016) and subsequent validation in AJCC 9th edition (Huang 2025) show superior survival compared to stage-matched HPV-negative disease. Multiple randomized trials (RTOG 1016, De-ESCALaTE) demonstrate that cisplatin-based chemoradiation yields better OS than cetuximab-based regimens [Gillison 2019, Mehanna 2019]. |
Prognostic Factors
- HPV/p16 status: Strongest prognostic factor for oropharyngeal cancer; p16+/HPV+ tumors have 5-year OS approximately 81% vs 40% for double negative [Mehanna 2023].
- Smoking history: Adverse impact on OS and PFS regardless of p16 status; never smokers have 51% reduction in progression risk vs current/former smokers with HPV+ disease [Gillison 2012, Lassen 2018].
- Extranodal extension (ENE): Negatively impacts survival in both HPV+ and HPV- disease; incorporated into AJCC 9th edition staging for HPV+ oropharynx [Ho 2025].
- Surgical margin status: Positive margins increase risk of local recurrence and are an indication for postoperative systemic therapy/RT (category 1) [Bernier 2004, Cooper 2004].
- Tumor stage and nodal stage: Advanced T and N categories are associated with worse survival across all subsites.
- Comorbidity: ACE-27 and Charlson Comorbidity Index are strong independent predictors of mortality [Piccirillo 2004].
- Age: Younger patients (<60) may benefit more from altered fractionation RT (MARCH meta-analysis) [Lacas 2017].
- Performance status: PS 0–1 is required for most intensive multimodality approaches; PS 2–4 limits treatment options and worsens outcomes.
Follow UpClick to collapse
Post Curative Treatment
Follow-up is based on risk of relapse, second primaries, treatment sequelae, and toxicities. The recommended schedule includes: Year 1, every 1–3 months; Year 2, every 2–6 months; Years 3–5, every 4–8 months; >5 years, every 12 months [FOLL-A 1 of 2]. Each visit should include a comprehensive head and neck examination (including mirror and fiberoptic examination as indicated). Most recurrences are reported by the patient. For patients with mucosal melanoma or paranasal sinus cancers, physical exam should include endoscopic inspection. TSH testing every 6–12 months is recommended if neck was irradiated and/or partial thyroidectomy was performed. Consider venous duplex ultrasound of the neck every 3 years if neck irradiated due to risk of carotid stenosis [Carpenter 2025]. Consider EBV DNA monitoring for EBER+ nasopharyngeal cancer (category 2B). Dental evaluation is needed for oral cavity and sites exposed to significant intraoral radiation. Survivorship care includes integration of a care plan within 1 year, complementary to ongoing head and neck oncology follow-up. Additional health monitoring and immunizations should be performed under the care of a primary care physician [Cohen 2016].
Surveillance Rationale
The majority of recurrences (70–80%) occur within the first 2 years after treatment. Surveillance is challenging due to altered anatomy, fibrosis, and edema from surgery, radiation, and chemotherapy. There are no consensus guidelines on the frequency and modality of routine post-treatment imaging in asymptomatic patients. FDG-PET/CT is the most sensitive modality for detecting recurrence, but early scans (<12 weeks) have high false-positive rates and should be avoided unless there is clinical suspicion. A negative PET/CT at 3 months post-treatment has a high negative predictive value; a second negative scan at 6 months allows suspension of radiologic assessment for asymptomatic patients [Heineman 2017, Cheung 2016]. In patients with HPV-related disease, delayed recurrences (>2 years) can occur, so long-term follow-up is warranted [Trosman 2015]. For patients with a substantial smoking history, annual chest CT may be considered for lung cancer screening. The role of imaging surveillance in asymptomatic patients is controversial; a retrospective study showed no significant difference in 3-year DFS between imaging and clinical surveillance (41% vs 46%, P=0.91) [Ho 2013].
Late Effects Screening
- Hypothyroidism: TSH every 6–12 months after neck irradiation.
- Hypopituitarism: Annual screening (AM cortisol, GH, free T4, prolactin, LH/FSH, ACTH, TSH, total and bioavailable testosterone) after RT to skull base (category 2B) [VanKoevering 2020].
- Carotid stenosis: Venous duplex ultrasound every 3 years if neck irradiated [Carpenter 2025].
- Dental caries and osteoradionecrosis: Regular dental evaluations with high-potency topical fluoride.
- Dysphagia and swallowing dysfunction: Speech-language pathology evaluation as clinically indicated; consider videofluoroscopic or fiberoptic swallowing studies.
- Xerostomia: Managed with saliva substitutes, stimulants, and dietary modifications.
- Lymphedema and fibrosis: Lymphatic decompression therapy; monitoring for progression.
- Hearing loss: Audiogram as clinically indicated.
- Second primary malignancies: Ongoing surveillance for lung, esophagus, and other tobacco/alcohol-related cancers.
- Emotional distress and depression: Regular screening using NCCN Distress Thermometer.
Recurrence Patterns
The majority of recurrences are locoregional (70–80% within 2 years). Distant metastases occur in approximately 10–20% of patients, more commonly in HPV-negative and advanced-stage disease. In HPV-positive oropharyngeal cancer, distant metastases can occur later and are more often oligometastatic. Second primary tumors (lung, esophagus, head and neck) are a significant risk, especially in tobacco/alcohol users, and require ongoing surveillance. For patients treated with induction chemotherapy, imaging (CT or MRI) is typically obtained after 2-3 cycles to assess response before definitive locoregional therapy [IMG-A 3 of 4]. After definitive RT-based treatment, FDG-PET/CT at 12 weeks is recommended to guide need for neck dissection. A planned neck dissection approach has been largely replaced by PET/CT surveillance in patients with N2–3 disease due to comparable outcomes and cost savings [Mehanna 2016].
Key TrialsClick to collapse
| Acronym | Full Name | Year | N | Intervention | Comparator | Population | Primary Endpoint | Key Result | Secondary Outcomes | Practice Change | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KEYNOTE-048 | Pembrolizumab Alone or with Chemotherapy versus Cetuximab with Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | 2019 | 882 | Pembrolizumab alone, or pembrolizumab + platinum/5-FU | EXTREME regimen (cetuximab + platinum/5-FU) | Recurrent or metastatic HNSCC, no prior systemic therapy for recurrent/metastatic disease (except if given as part of multimodal treatment completed >6 months prior) | Overall survival in CPS ≥1 population (pembrolizumab alone) and total population (pembrolizumab + chemotherapy) | Pembrolizumab + chemo improved OS vs EXTREME in total population (median 13.0 vs 10.7 months; HR 0.77; 95% CI 0.63–0.93; P=0.003). Pembrolizumab alone improved OS vs EXTREME in CPS ≥20 (median 14.9 vs 10.7 months; HR 0.61; 95% CI 0.45–0.83) and CPS ≥1 (median 12.3 vs 10.3 months; HR 0.78; 95% CI 0.64–0.96). | PFS not different between pembrolizumab + chemo and EXTREME; longer duration of response with pembrolizumab. Long-term follow-up (Harrington 2023) confirmed OS benefit. | Established pembrolizumab alone (for CPS ≥1) and pembrolizumab + platinum/5-FU (any CPS) as preferred first-line therapy for recurrent/metastatic HNSCC. | Lancet |
| KEYNOTE-689 | Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | 2025 | 714 | Neoadjuvant pembrolizumab → surgery → adjuvant pembrolizumab/RT (with cisplatin if ENE/positive margin) → adjuvant pembrolizumab | Placebo → surgery → adjuvant RT ± cisplatin (standard of care) | Resectable locally advanced HNSCC (stage III–IVA), PD-L1 CPS ≥1; >95% HPV-negative | Event-free survival (EFS) in CPS ≥10 (by BICR) | 36-month EFS: 59.8% (pembrolizumab) vs 45.9% (control) in CPS ≥10 (HR 0.66; 95% CI 0.49–0.88; P=0.004); 58.2% vs 44.9% in CPS ≥1 (HR 0.70; 95% CI 0.55–0.89; P=0.003). OS not yet significant. | Pathological complete response 3.0% in total population; major pathological response 9.3%. Reduced distant metastases rate. Higher TRAEs grade ≥3: 44.6% vs 42.9%. | Led to FDA approval of neoadjuvant/adjuvant pembrolizumab for resectable, PD-L1 positive (CPS ≥1) locally advanced SCCHN. Now included in NCCN Guidelines as an option for eligible oral cavity, p16-negative oropharynx, hypopharynx, and larynx cancers. | New England Journal of Medicine |
| CheckMate 141 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | 2016 | 361 | Nivolumab 3 mg/kg every 2 weeks | Standard single-agent therapy (methotrexate, docetaxel, or cetuximab) | Recurrent SCCHN with progression within 6 months of platinum-based chemotherapy | Overall survival | Median OS 7.5 months (nivolumab) vs 5.1 months (standard); HR 0.70; 97.73% CI 0.51–0.96; P=0.01. 1-year OS 36.0% vs 16.6%. | ORR 13.3% vs 5.8%; median PFS not significantly different (2.0 vs 2.3 months). | Established nivolumab as standard second-line therapy for platinum-refractory recurrent/metastatic HNSCC (category 1). Two FDA-approved dosing regimens: 240 mg every 2 weeks or 480 mg every 4 weeks. | New England Journal of Medicine |
| RTOG 91-11 | Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients with Locally Advanced Larynx Cancer | 2013 (initial 2003) | 520 | Arm 1: Induction cisplatin/5-FU → RT; Arm 2: Concurrent cisplatin/RT; Arm 3: RT alone | All arms allowed salvage laryngectomy | Stage III–IV laryngeal cancer (excluding T1 and high-volume T4) | Larynx preservation, overall survival, locoregional control | 2-year larynx preservation: 88% (concurrent), 74% (induction), 69% (RT alone) – significantly better for concurrent. No significant OS difference between arms at long-term follow-up (10-year OS not different). More non-cancer deaths in concurrent arm. | Locoregional control better with concurrent. Late toxicity similar. | Concurrent cisplatin/RT became the preferred larynx preservation strategy for advanced laryngeal cancer requiring total laryngectomy. | Journal of Clinical Oncology |
| JUPITER-02 | Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial | 2023 | 289 | Toripalimab + gemcitabine/cisplatin | Placebo + gemcitabine/cisplatin | Recurrent or metastatic nasopharyngeal carcinoma, no prior systemic therapy for recurrent/metastatic disease | Progression-free survival (by independent review committee) | Median PFS 21.4 months (toripalimab) vs 8.2 months (placebo); HR 0.52; 95% CI 0.37–0.73. OS HR 0.63 (not yet reached vs 33.7 months). ORR 78.8% vs 64.6%. | Duration of response longer; manageable toxicity. | Toripalimab + GC became preferred first-line therapy for recurrent/metastatic NPC (category 1). Toripalimab monotherapy also preferred for subsequent-line (category 1) [Wang 2021 POLARIS-02]. | Journal of the American Medical Association |
| RTOG 9501 / EORTC 22931 | Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck (and parallel EORTC trial) | 2004 | RTOG: 416; EORTC: 334 | Postoperative cisplatin (100 mg/m2 q3wk × 3) + RT (60–66 Gy) | Postoperative RT alone | High-risk resected SCCHN (RTOG: ≥2 positive nodes, positive margins, or ENE; EORTC: also perineural/vascular invasion, level IV/V nodes from oral cavity/oropharynx) | Locoregional control (RTOG); OS (EORTC) | EORTC: improved OS (P=0.02) and progression-free survival. RTOG: improved locoregional control and DFS, but not OS. Combined analysis showed benefit only in patients with ENE and/or positive margins [Bernier 2005]. | Increased acute toxicity with combination. | Established cisplatin + RT as standard postoperative therapy for high-risk features (ENE and/or positive margins, category 1). Postoperative RT alone for intermediate-risk features. | New England Journal of Medicine |
| EXTREME | Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer | 2008 | 442 | Cetuximab + cisplatin or carboplatin + 5-FU | Cisplatin or carboplatin + 5-FU alone | Recurrent or metastatic SCCHN, no prior systemic therapy for recurrent/metastatic disease | Overall survival | Median OS 10.1 vs 7.4 months (HR 0.80; 95% CI 0.64–0.99; P=0.04). ORR 36% vs 20% (P<0.001). | PFS improved (5.6 vs 3.3 months; P<0.001). | Established the EXTREME regimen as first-line palliative therapy for recurrent/metastatic SCCHN. Now largely replaced by pembrolizumab-based regimens as preferred first-line. | New England Journal of Medicine |
Clinical PearlsClick to collapse
- Pearl 1: Always test for p16 (by IHC) in all oropharyngeal cancers; patients with p16+ and HPV+ tumors have significantly better prognosis than those with discordant or double-negative disease [Mehanna 2023]. Confirmatory HPV testing (PCR or RNA ISH) is recommended in low-prevalence regions, clinical trials, and cases with equivocal p16 [ORPH-B].
- Pearl 2: For resectable oral cavity cancer, surgery is the standard of care. Depth of invasion >3 mm warrants elective neck dissection [D'Cruz 2015]. Sentinel lymph node biopsy is an alternative in experienced centers for T1–T2 N0 oral cavity cancers [SURG-A 7 of 9].
- Pearl 3: Concurrent high-dose cisplatin (100 mg/m2 every 3 weeks) with RT remains the gold standard for definitive chemoradiation in fit patients with locally advanced SCCHN. Weekly cisplatin 40 mg/m2 is a reasonable alternative for patients with toxicity concerns, but doses <40 mg/m2 should not be used due to inferior locoregional control [Noronha 2018, Kiyota 2022].
- Pearl 4: IMRT is the preferred radiation technique for most head and neck sites to reduce xerostomia and other late toxicities [Nutting 2011]. Proton therapy is an option when normal tissue constraints cannot be met with IMRT, particularly for skull base, sinonasal, and reirradiation cases [RAD-A 2 of 7].
- Pearl 5: For patients with metastatic or recurrent SCCHN, first-line therapy with pembrolizumab alone (if PD-L1 CPS ≥1, category 1) or pembrolizumab + platinum/5-FU (any CPS, category 1) is preferred over the EXTREME regimen based on KEYNOTE-048 [Burtness 2019]. Nivolumab is category 1 for platinum-refractory disease [Ferris 2016].
- Pearl 6: Larynx preservation strategies: For T3 laryngeal cancer requiring total laryngectomy, concurrent cisplatin/RT offers the highest larynx preservation rate (88% at 2 years) based on RTOG 91-11 [Forastiere 2003, 2013]. Induction chemotherapy (TPF) followed by RT is an alternative for organ preservation.
- Pearl 7: Plasma EBV DNA is a key prognostic marker in nasopharyngeal carcinoma; high levels at baseline and persistence after chemoradiation are associated with poorer outcomes. Consider monitoring for EBER+ disease (category 2B). Plasma EBV DNA has superior sensitivity (~97%) for early-stage detection [Lou 2023].
- Pearl 8: For salivary gland tumors, multigene panel testing (including AR, HER2, NTRK, FGFR, BRAF, RET, MSI, TMB, PD-L1) is recommended for advanced or metastatic disease to identify actionable targets [SALI-B]. Androgen receptor therapy for AR+ tumors and NTRK inhibitors for NTRK fusion-positive tumors are effective options.
- Pearl 9: Osteoradionecrosis prevention: Complete dental evaluation and extractions (if needed) should be performed at least 2 weeks before RT. Use high-potency topical fluoride (1.1% NaF) daily lifelong. For established ORN, consult with radiation oncologist before any dental implants or extractions [DENT-A].
- Pearl 10: Venous duplex ultrasound of the neck every 3 years is recommended for patients who received neck irradiation, due to cumulative risk of carotid stenosis (up to 30% at 10 years) [Carpenter 2025].
Special SituationsClick to collapse
Cisplatin-ineligible patients (advanced age, renal impairment, hearing loss, neuropathy, poor PS) requiring chemoradiation
De-escalation for HPV-positive oropharyngeal cancer
Reirradiation for locoregional recurrence
Oligometastatic disease (newly diagnosed or recurrent with limited metastases)
Perioperative immunotherapy in resectable locally advanced SCCHN (KEYNOTE-689)
Adjuvant nivolumab in high-risk resected SCCHN (NIVOPOSTOP)
Toripalimab for recurrent/metastatic nasopharyngeal carcinoma
Guidelines ResourcesClick to collapse
NCCN Guidelines for Head and Neck Cancers (Version 2.2026)
NCCN Guidelines for Patients: Head and Neck Cancers
AJCC Cancer Staging Manual, 9th edition (2025)
Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline Update (2025)
Transoral Robotic Surgery in the Multidisciplinary Care of Patients with Oropharyngeal Squamous Cell Carcinoma (2025)
Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: Executive Summary of an ASTRO Evidence-Based Clinical Practice Guideline (2017)
Head and Neck Cancer Survivorship Care Guideline (2016)
Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy (2024)
Protective FactorsClick to collapse
- HPV vaccination: vaccination against HPV types 6, 11, 16, 18 (and nonavalent vaccine covering additional high-risk types) reduces oral HPV infections. Data from NHANES 2011-2014 show reduced vaccine-type oral HPV prevalence in vaccinated individuals (0.1% vs. 1.6%, P = .008) [Discussion MS-4; Chaturvedi et al. 2018]. The FDA expanded the HPV vaccine indication to include prevention of oropharyngeal cancer [Discussion MS-4].
- Smoking cessation: quitting smoking reduces the risk of head and neck cancer and improves treatment outcomes. The risk of developing cancer declines after cessation, approaching that of never-smokers after 10-20 years [Discussion MS-5]. All patients should be advised to quit and remain abstinent, especially during radiotherapy [TEAM-1].
- Alcohol moderation: reducing alcohol intake lowers risk of oral cavity, pharyngeal, and laryngeal cancers. Combining smoking cessation with alcohol reduction provides synergistic benefit [Discussion MS-5].
- Diet and nutrition: high intake of fruits and vegetables, particularly those rich in carotenoids and vitamin C, may reduce risk of oral and pharyngeal cancers. The evidence is supportive but not definitive [Discussion MS-5].
- Oral and dental care: regular dental care and maintaining oral hygiene may reduce risk of oral cavity cancer by limiting chronic inflammation and infection [DENT-A].
- Occupational exposure controls: reducing exposure to wood dust, leather dust, and formaldehyde through ventilation, protective equipment, and industrial hygiene lowers risk of sinonasal cancers [Discussion MS-52].
- EBV screening in endemic regions: plasma EBV DNA testing can detect early-stage nasopharyngeal carcinoma, allowing for earlier diagnosis and improved outcomes. In high-risk populations, screening has been shown to increase the proportion of early-stage diagnoses [NASO-1; Discussion MS-41].